Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
332
datasets available to search
ShareScore release 0.9.0
Dataset results
332 results for “primary prevention”
Data and code: A Comparison of Contemporary versus Older Studies of Aspirin for Primary Prevention
<p>Data (comma-separated values format) and analytical code (Stata format) relating to: Moriarty F, Ebell MH. A Comparison of Contemporary versus Older Studies of Aspirin for Primary Prevention. 2019 (under review). Available on medRxiv at https://doi.org/10.1101/19004267</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Purpose</strong>: This study compares the benefits and harms of aspirin for primary prevention before and after widespread use of statins and colorectal cancer screening.</p> <p><strong>Methods: </strong>We compared studies of aspirin for primary prevention that recruited patients from 2005 onward with previous individual patient meta-analyses that recruited patients from 1978 to 2002. Data for contemporary studies were synthesized using random-effects models. We report vascular (major adverse cardiovascular events [MACE], myocardial infarction [MI], stroke), bleeding, cancer, and mortality outcomes.</p> <p><strong>Results</strong>: The IPD analyses of older studies included 95,456 patients for CV prevention and 25,270 for cancer mortality, while the four newer studies had 61,604 patients. Relative risks for vascular outcomes for older vs newer studies follow: MACE: 0.89 (95% CI 0.83-0.95) vs 0.93 (0.86-0.99); fatal hemorrhagic stroke: 1.73 (1.11-2.72) vs 1.06 (0.66-1.70); any ischemic stroke: 0.86 (0.74-1.00) vs 0.86 (0.75-0.98); any MI: 0.84 (0.77-0.92) vs 0.88 (0.77-1.00); and non-fatal MI: 0.79 (0.71-0.88) vs 0.94 (0.83-1.08). Cancer death was not significantly decreased in newer studies (RR 1.11, 0.92-1.34). Major hemorrhage was significantly increased for both older and newer studies (RR 1.48, 95% CI 1.25-1.76 vs 1.37, 95% CI 1.24-1.53). There was no effect in either group on all-cause mortality, cardiovascular mortality, fatal stroke, or fatal MI.</p> <p><strong>Conclusions</strong>: In the modern era characterized by widespread statin use and cancer screening, aspirin does not reduce the risk of non-fatal MI or cancer death. There are no mortality benefits and a significant risk of major hemorrhage. Aspirin should no longer be recommended for primary prevention.</p> <p> </p> <p>Version 1.1 - Updated Stata code to correct name of .csv data file for import.</p>
The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis
<p>Meta data for the review entitled "The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis<strong>"</strong></p>
Isoniazid Preventive Therapy (IPT) uptake and Tuberculin Skin Test (TST) uptake among adults receiving primary HIV care in South Africa .
<p>We aimed to evaluate Isoniazid Preventive Therapy (IPT) and tuberculin skin testing (TST) uptake under primary care clinic conditions, and determine health care worker (HCW) fidelity to the 2014 South African IPT guidelines. Following training on IPT guidelines and tuberculin skin testing (TST), 3 primary care clinics identified their IPT implementation strategy in a participatory manner. Using routine register data, TST uptake was determined 3 months before and 5 months after the intervention. Records were reviewed to identify IPT/TST uptake and factors associated with IPT initiation among adults living with HIV.</p>
Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
ClinicalTrials.gov study NCT00603590. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
ClinicalTrials.gov study NCT02923726. IPD Sharing: NO. Countries: 8. Publications: 1.
Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs
ClinicalTrials.gov study NCT03282890. IPD Sharing: NO. Countries: 1. Publications: 11.
Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
ClinicalTrials.gov study NCT02732730. IPD Sharing: NO. Countries: 2. Publications: 11.
TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk
ClinicalTrials.gov study NCT00179777. IPD Sharing: NO. Countries: 15. Publications: 13.
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
ClinicalTrials.gov study NCT01672853. IPD Sharing: Not stated. Countries: 10. Publications: 3.
Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care
ClinicalTrials.gov study NCT07252700. IPD Sharing: NO. Countries: 1. Publications: 19.
Evaluation of a Primary Type 2 Diabetes Prevention Programme
ClinicalTrials.gov study NCT00707447. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Green Dot a Primary Prevention Intervention
ClinicalTrials.gov study NCT01878097. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
ClinicalTrials.gov study NCT01688141. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction
ClinicalTrials.gov study NCT02433379. IPD Sharing: NO. Countries: 13. Publications: 4.
Primary Care Prevention of Stimulant Diversion by High School Students With ADHD
ClinicalTrials.gov study NCT03080259. IPD Sharing: YES. Countries: 1. Publications: 3.
The Primary Prevention of Intimate Partner Violence
ClinicalTrials.gov study NCT06811922. IPD Sharing: YES. Countries: 1. Publications: 0.
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
ClinicalTrials.gov study NCT02958969. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Adolescent Substance Use Prevention Intervention Research Study in Pediatric Primary Care
ClinicalTrials.gov study NCT04450966. IPD Sharing: YES. Countries: 1. Publications: 1.
Technology-Based Prevention for Adolescents in Primary Care
ClinicalTrials.gov study NCT03489434. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
ClinicalTrials.gov study NCT00251979. IPD Sharing: Not stated. Countries: 16. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.